256 related articles for article (PubMed ID: 1539312)
1. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
2. Five-year experience with a triple drug protocol in renal transplantation.
Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
[No Abstract] [Full Text] [Related]
3. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
4. Triple drug maintenance therapy in renal transplantation.
Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
[No Abstract] [Full Text] [Related]
5. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
Buturović-Ponikvar J; Kandus A; Malovrh M; Ponikvar R; Kveder R
Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
[No Abstract] [Full Text] [Related]
6. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
7. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
8. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
9. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
10. OKT3 for steroid-resistant renal allograft rejection: differential response in adults and children.
Shmueli D; Nakache R; Lustig S; Bar Nathan N; Yussim A; Shaharabani E; Geier A; Shapira Z
Transplant Proc; 1994 Aug; 26(4):1948-9. PubMed ID: 8066630
[No Abstract] [Full Text] [Related]
11. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
[No Abstract] [Full Text] [Related]
12. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
[No Abstract] [Full Text] [Related]
13. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
[No Abstract] [Full Text] [Related]
14. Treatment of steroid resistant acute rejection after renal transplantation.
Oh CK; Kim YS; Kim MS; Kim SI; Park K
Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
[No Abstract] [Full Text] [Related]
15. Clinical results of quadruple drug immunosuppression in liver transplantation.
Fabregat J; Fradera R; Jaurrieta E; Figueras J; Rafecas A; Rufi G; Casanovas T; Casais L; Gil Vernet S
Transplant Proc; 1992 Feb; 24(1):148-9. PubMed ID: 1539217
[No Abstract] [Full Text] [Related]
16. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study.
Cherqui D; Duvoux C; Salvat A; Lauzet JY; Metreau JM; Julien M; Fagniez PL; Dhumeaux D
Transplant Proc; 1995 Feb; 27(1):1134-5. PubMed ID: 7878824
[No Abstract] [Full Text] [Related]
17. Monitoring of donor sensitization in kidney transplant recipients by flow cytometric crossmatch.
Cinti P; Bachetoni A; Baiano V; Pretagostini R; Poli L; Berloco P; Renna Molajoni E; Cortesini R
Transplant Proc; 1993 Dec; 25(6):3265-6. PubMed ID: 8266536
[No Abstract] [Full Text] [Related]
18. Posttransplant renal allograft dysfunction as a prognostic factor in triple therapy-treated patients.
Pallardó LM; García J; Sánchez J; Górriz JL; Orero E; Calabuig F
Transplant Proc; 1992 Feb; 24(1):113-4. PubMed ID: 1539199
[No Abstract] [Full Text] [Related]
19. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
20. Is HLA matching worthwhile in pancreatic transplantation?
Hopt UT; Büsing M; Schareck W; Pfeffer F; Irkin I; Becker HD
Transplant Proc; 1992 Jun; 24(3):909-10. PubMed ID: 1604664
[No Abstract] [Full Text] [Related]
[Next] [New Search]